KRAS as a druggable target in NSCLC: rising like a phoenix after decades of development failures

Accounting for 18% of all cancer-related deaths, lung cancer is the leading cause of cancer-related mortality worldwide[1]. It comprises two main subtypes, small-cell and non-small-cell lung cancer (NSCLC), the latter representing over 80% of lung cancers. NSCLC is further divided by histologic subtypes. Adenocarcinoma (ADC) (60%) and squamous cell carcinoma (SCC) (35%) are the most common, each with distinct genomic profiles [2,3]. Until recently, the prognosis of advanced NSCLC was dire due to limited therapeutic options, with a 5-year survival rate under 5%[4].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Hot Topic Source Type: research